Nolu Review: A Clean Floor Price, No Names Behind It

The one-sentence version

Nolu is a general-wellness telehealth brand selling NAD+ and compounded sermorelin from a published "From $145/mo" floor — a real number, visible with no quiz gate — attached to no dose-level detail and no named medical director, prescriber, or compounding pharmacy anywhere on the site. It grades B, 8 points out of 14, computed from published terms alone.

What it is, and who it's for

Nolu markets itself broadly as a longevity/wellness brand rather than a specialist clinic. Its Energy & Recovery line pairs NAD+ with compounded sermorelin vials, published from $145/month. A separate Microdose GLP-1 + B12/NAD+ stack runs from $179/month, in two variants the site names Core and Energy & Focus — the latter is the more relevant of the two for a reader who wants NAD+ alongside a GLP-1 microdose rather than as a standalone line. LegitScript verified, and stated to serve all 50 states plus DC ("subject to change").

The buyer this suits is someone comparison-shopping who wants a real starting number without an email-gated quiz. The buyer it does not suit is someone who wants to know what a specific protocol costs before signing up, or who wants a named clinician behind the prescription.

What it actually costs

On Nolu's own site, the Energy & Recovery line — NAD+ and compounded sermorelin — is published "From $145/mo," with no dose-level ladder shown on the page: it is not stated what that floor buys, whether a higher dose costs more, or whether the figure is a true month-to-month rate or requires a plan length to reach. The separate Microdose GLP-1 + B12/NAD+ stack runs "From $179/mo," likewise with no breakdown by variant.

Our rubric credits a provider for publishing one all-in figure before a reader commits, and "$145/mo" clears that bar as a genuine, ungated number — nothing on the page suggests it is a prepay-only rate the way several partner rows here are. But it does not resolve what the actual prescribed protocol costs, which is the gap the Telos Rx review and the Wellorithm review both document in their own providers: a published floor is not the same thing as a published price.

Clinical oversight and the pharmacy

This is where Nolu is thinnest. The site references "licensed US providers" and "US-regulated pharmacies" in generic terms; no medical director, individual prescriber, or compounding pharmacy is named anywhere we could find. That is a genuine gap against the standard this site applies evenly: a provider that publishes a 503A claim on any surface it controls — its own site, help center, or press material — scores on our pharmacy test even without naming the facility. Nolu makes no such claim at all, which is why it scores zero on that factor rather than the partial credit a "compounded in the USA" line elsewhere here sometimes earns.

What the research says, in short

Nolu's marketing does not lean on cognition-specific claims, and that restraint is worth noting. The sermorelin it sells is compounded, and compounded drugs are not FDA-approved: FDA does not verify their safety, effectiveness or quality before they are marketed¹. Human evidence that NAD+ or sermorelin slows aging in healthy adults is still thin. See NAD+ for longevity and peptides for longevity.

Where it's weak, and who should skip it

Skip it if you want to know what your specific protocol costs before you start — "from $145/mo" is a floor, not a quote. Skip it if a named clinician or a named pharmacy matters to you, because Nolu names neither. If you proceed, ask for the full dose-level price ladder in writing and confirm whether $145 is a true month-to-month rate or requires a longer plan to reach.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). Nolu takes the full four for publishing a real, ungated starting price, and four for a genuine NAD+/sermorelin longevity line — and zero on the remaining three: zero on clinical oversight, because no consult inclusion is stated; zero on pharmacy, because nothing is named or classified; zero on human support, which the site does not claim. Eight of fourteen: a B. Two neighbors added the same day are our CeliaRx review and FORM (by GBY) review; the full field is at our provider rankings.